Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid.
Alzheimer's disease (AD) therapies predominantly focus on β-amyloid (Aβ), but Aβ effects may be maximal before clinical symptoms appear. Downstream of Aβ, dendritic spine loss...